Forte Biosciences, Inc. (FBRX): Price and Financial Metrics


Forte Biosciences, Inc. (FBRX): $1.01

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FBRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FBRX Stock Price Chart Interactive Chart >

Price chart for FBRX

FBRX Price/Volume Stats

Current price $1.01 52-week high $1.78
Prev. close $1.01 52-week low $0.90
Day low $0.98 Volume 47,600
Day high $1.02 Avg. volume 40,678
50-day MA $1.00 Dividend yield N/A
200-day MA $1.16 Market Cap 20.54M

Forte Biosciences, Inc. (FBRX) Company Bio


Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.


FBRX Latest News Stream


Event/Time News Detail
Loading, please wait...

FBRX Latest Social Stream


Loading social stream, please wait...

View Full FBRX Social Stream

Latest FBRX News From Around the Web

Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.

Forte Biosciences GAAP EPS of -$0.18 misses by $0.03

Forte Biosciences press release (FBRX): Q3 GAAP EPS of -$0.18 misses by $0.03.“Forte is making excellent progress with its lead program FB-102, which is a direct result of the…

Seeking Alpha | November 15, 2022

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served

Wallstreet:Online | November 14, 2022

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. “Forte is making excellent progress with its lead program FB-102, which is a direct result of the team’s hard work and diligent efforts. FB-102 holds significant potential in a variety of indications

Wallstreet:Online | November 14, 2022

Large Forte Biosciences shareholder scolds company board of directors

Funicular Funds, which owns 8% of the outstanding shares of Forte Biosciences (FBRX), excoriated the company board of directors in a letter over a recent capital raise.

Seeking Alpha | August 24, 2022

Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise

NEW YORK, August 17, 2022--Camac Partners, LLC (together with its affiliates, "Camac" or "we"), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today expressed concerns regarding the Company’s sizable trading price discount relative to its cash on hand and the Board of Directors’ (the "Board") decision to conduct a highly dilutive equity capital raise following the emergence of four separate Schedule 13D filers.

Yahoo | August 17, 2022

Read More 'FBRX' Stories Here

FBRX Price Returns

1-mo -1.94%
3-mo -7.76%
6-mo -12.17%
1-year -34.42%
3-year -22.39%
5-year -96.99%
YTD 1.00%
2022 -53.27%
2021 -64.73%
2020 355.24%
2019 -93.51%
2018 -19.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7388 seconds.